Wait for the ricochet

The conclusion that there was nothing wrong with the specifics of the TeGenero trial in which six healthy volunteers ended up in intensive care has repercussions for the wider biotech industry.

UK Chroma gets £30M for clinical trials

Chroma Therapeutics Ltd raised £30 million in a third private round, giving the chromatin specialist funding for the next three years and enabling it to advance the lead programme through Phase II clinical studies and bring two further products into the clinic.

Patent auction: many low bids, but some successes

Lots of buzz preceded what was billed as the world's first live, multi-lot technology patent auction on April 6, but reality failed to meet expectations for many of the inventors who put up 400-plus patents for sale.

Agency orders probe into clinical trials procedures

After finding nothing wrong with the specifics of the preclinical data, the product, or how the trial was conducted, the UK Medicines and Healthcare Products Regulatory Agency has ordered an investigation to changes in clinical trials procedures.

Intellectual Property: Patents hit the auction block

A Chicago merchant bank will take a new twist on selling intellectual property next week when it holds a live auction to sell 400-plus patents from some of the most valued technology innovators in the world. Lori Valigra looks at the list.

Swedish biotech: where's the beef?

Sweden is ranked number one among 31 European nations for its spending on R&D - but it is still looking for its first home-grown biotechnology product.

US Supreme Court examines key patent issues

Tectonic shifts in the patent landscape could follow on from high-profile lawsuits challenging what can be protected by a patent and how patents are enforced that are due to be heard by the US Supreme Court this month.